Status:
COMPLETED
Safety and Tolerability of Autologous Adipose-derived Mesenchymal Stem Cells Therapy in Adults With Atrophic Scars
Lead Sponsor:
CellinCells
Conditions:
Atrophic Scar
Eligibility:
All Genders
19+ years
Phase:
PHASE1
Brief Summary
The purpose of this clinical trial was to evaluate the safety and tolerability for 12 weeks after one dose of TRTP-101 in adults with atrophic scars.
Detailed Description
A phase 1 clinical trial to evaluate dose-limiting toxicity by administering a singe dose of TRTP-101 to each of the four sites of atrophic scar.
Eligibility Criteria
Inclusion
- Male or Female aged greater than 19 years
- Four or more atrophic scars in the joints, genitals, perineum, and face except for the lips, eyes and nose
Exclusion
- History of cell therapy
- Treatment of Dermal resurfacing, Chemical/Mechanical Peel and Skin Photorejuvenation
- Treatment of Hyaluronic acid/collagen skin filler, non-permanent soft tissue filler and fat grafting
- Positive for virus infection
- Use of Anticoagulant therapy or NSAIDs
- Thrombocytopenia or other coagulation disorder
- History of keloid scars
- Infectious disease or other dermatitis in the area of the atrophic scar
- Use of Immunosuppressant, immunomodulating drug, anticancer drug or radiation therapy
- Use of systemic steroid medication
- History of hypersensitivity or severe allergic reactions (e.g., anaphylaxis, Guillain-Barre syndrome, etc.)
- Use of retinoid medications
Key Trial Info
Start Date :
December 6 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 28 2025
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT06210919
Start Date
December 6 2023
End Date
March 28 2025
Last Update
August 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samsung Medical Center
Seoul, South Korea